Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Engage Grants Program

University of British Columbia

$25,000.00

Characterizing the impact of a novel therapeutic on the infection strategy of pathogens

EF 2015-16

Résumé
Salmonella infections represent a significant public health concern and disease burden. Significant sources of infection are typically contaminated meat and poultry, eggs, and fresh produce. As such, the control of Salmonella infections in poultry products is one means to reduce human infections. While advances have been made in reducing the frequency of Salmonella contamination in processed poultry, there is mounting pressure on commercial producers to prevent and/or eliminate these pathogens in pre-harvest production facilities. NovoBind Livestock Therapeutics Inc. proposes to develop a novel antibody-based therapeutic strategy that could be provided to commercial growers to prevent and/or eliminate Salmonella pathogens in pre-harvest poultry production facilities. Currently, novel Salmonella-specific antibodies have been generated and are being tested for their efficacy using in vitro and in vivo methods. The work proposed here capitalizes on the expertise of Dr. Michael Murphy in the fields of protein biochemistry, biophysics, and structural biology. This project proposes to: (1) optimize the protein purity and yields of NovoBind's novel antibodies and antigens in order to conduct unique proof of concept experiments, (2) measure the strength of binding between antibodies and antigens, and (3) begin to map the interaction between the most promising antibody/antigen combinations. The development of a Salmonella-selective and highly effective antibody would benefit Canadian and World populations by reducing human infection and illness, loss of life and costs of treatment. The revenue generated by NovoBind in delivering this product would also be an economic boost to Canada.
Programme
Engage Grants Program
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data

Tel que publié

Application id
491902-2015
Name nom
Murphy, Michael
Department département
Microbiology and Immunology
Organization id
2
Institution établissement
University of British Columbia
Province en
British Columbia
Province fr
Colombie-Britannique
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2015
Competition year année de concours
2015
Award amount
25000
Program id
EGP
Program name en
Engage Grants Program
Program name fr
Programme de subventions d'engagement partenariat
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1554
Committee name en
Pacific Internal Decision Committee
Committee name fr
Comité de décision interne pour le Pacifique
Area of application code
1209
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Agriculture
Area of application fr
Agriculture
Research subject code
5400
Research subject group en
Biochemistry
Research subject group fr
Biochimie
Research subject en
Biochemistry
Research subject fr
Biochimie
Partie
1
Nb partie
1
Application title
Characterizing the impact of a novel therapeutic on the infection strategy of pathogens
Keyword
NSERC
Application summary
Salmonella infections represent a significant public health concern and disease burden. Significant sources of infection are typically contaminated meat and poultry, eggs, and fresh produce. As such, the control of Salmonella infections in poultry products is one means to reduce human infections. While advances have been made in reducing the frequency of Salmonella contamination in processed poultry, there is mounting pressure on commercial producers to prevent and/or eliminate these pathogens in pre-harvest production facilities. NovoBind Livestock Therapeutics Inc. proposes to develop a novel antibody-based therapeutic strategy that could be provided to commercial growers to prevent and/or eliminate Salmonella pathogens in pre-harvest poultry production facilities. Currently, novel Salmonella-specific antibodies have been generated and are being tested for their efficacy using in vitro and in vivo methods. The work proposed here capitalizes on the expertise of Dr. Michael Murphy in the fields of protein biochemistry, biophysics, and structural biology. This project proposes to: (1) optimize the protein purity and yields of NovoBind's novel antibodies and antigens in order to conduct unique proof of concept experiments, (2) measure the strength of binding between antibodies and antigens, and (3) begin to map the interaction between the most promising antibody/antigen combinations. The development of a Salmonella-selective and highly effective antibody would benefit Canadian and World populations by reducing human infection and illness, loss of life and costs of treatment. The revenue generated by NovoBind in delivering this product would also be an economic boost to Canada.